On July 8, the Ark Genomic Revolution ETF sold roughly $7.4 million worth of BioNTech stock. Cathie Wood's ETF has now almost completely sold its entire position in BioNTech.

fool.com - 2026-07-14 09:42:00

They may not remain cheap for too much longer.

fool.com - 2026-07-07 18:30:00

BioNTech has held confidential talks with potential buyers about ​the German sites that the ‌COVID‑19 vaccine maker plans to close, which has now grown to four locations, ​the Handelsblatt newspaper reported on ​Friday.

reuters.com - 2026-07-03 01:51:40

U.S. pharmaceutical company ​Moderna is interested ‌in investing in production facilities in ​Germany, with ​an eye on ⁠plants that its ​German rival ​BioNTech plans to close, CEO Stephane Bancel ​told the ​German business daily Handelsblatt ‌on ⁠Wednesday.

reuters.com - 2026-06-17 02:38:57

Arcus Biosciences teams up with Bristol Myers Squibb to test casdatifan combinations in kidney cancer, expanding its ccRCC development strategy.

zacks.com - 2026-06-04 12:55:34

BMY unveils strong ASCO data for mezigdomide and pumitamig, highlighting late-stage pipeline progress across myeloma and lung cancer.

zacks.com - 2026-06-01 11:01:12

First investigational PD-(L)1xVEGF bispecific immunomodulator to present global data showing encouraging efficacy in combination with chemotherapy in first-line non-small cell lung cancer across PD-L1 expression levels and subtypes, highlighting its potential to set a new standard of care Pumitamig plus chemotherapy showed robust and consistent antitumor activity in first-line non-small cell lung cancer at both evaluated dose levels, with higher confirmed objective response rates at the lower dose of 63.6% in the non-squamous and 72.7% in the squamous subtypes Pumitamig is advancing through a comprehensive global Phase 3 development program in non-small cell lung cancer, including the actively enrolling pivotal Phase 3 part of the ROSETTA Lung-02 trial, along with two additional global Phase 3 trials MAINZ, Germany, and PRINCETON, USA, May 30, 2026 – BioNTech SE (Nasdaq: BNTX, “BioNTech”) and Bristol Myers Squibb Company (NYSE: BMY, “BMS”) today announced interim Phase 2 data from the global Phase 2/3 ROSETTA Lung-02 clinical trial (NCT06712316) evaluating the investigational PD-L1xVEGF-A bispecific immunomodulator pumitamig (also known as BNT327 or BMS-986545) plus chemotherapy in patients with previously untreated advanced non-small cell lung cancer (“NSCLC”). The data showed encouraging anti-tumor activity, with high response rates observed in both non-squamous and squamous NSCLC and at each PD-L1 expression level (TPS ˂ 1%, TPS 1 – 49%, and TPS ≥ 50%).

globenewswire.com - 2026-05-30 14:15:00

Pumitamig data from the ongoing Phase 2/3 ROSETTA Lung-02 trial in first-line non-small cell lung cancer mark the third global data set to consistently show encouraging anti-tumor activity for pumitamig in combination with chemotherapy Gotistobart Phase 2 overall survival data in patients with platinum-resistant ovarian cancer add to the growing body of evidence supporting its potential as a chemotherapy-free treatment option Continued advancement of late-stage oncology pipeline with 25+ Phase 2 and Phase 3 clinical trials, including 13 ongoing pivotal trials as well as novel-novel combination trials across major cancer types MAINZ, Germany, May 22, 2026 – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will present new clinical data and trial updates from its late-stage oncology pipeline and innovative combination programs at the 2026 American Society of Clinical Oncology (“ASCO”) Annual Meeting held in Chicago, from May 29 to June 02. Two oral presentations will highlight new data for key strategic assets pumitamig and gotistobart.

globenewswire.com - 2026-05-22 05:00:00

MAINZ, Germany, May 15, 2026 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) held its Annual General Meeting (“AGM”) today. A total of 92 per cent of the share capital was represented at the virtual assembly.

globenewswire.com - 2026-05-15 16:15:00

BioNTech NASDAQ: BNTX used its virtual annual general meeting to outline a transition year marked by leadership changes, continued investment in oncology, a planned share repurchase program and a restructuring of its manufacturing network.

marketbeat.com - 2026-05-15 12:10:34

The hantavirus isn't as contagious as the coronavirus, making a global pandemic unlikely. Picking the potential winners in the hantavirus vaccine market would hardly be worth the time and risk.

fool.com - 2026-05-13 13:15:00

MAINZ, Germany, May 7, 2026 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) today announced that it has authorized a new share repurchase program (the “Program”), under which the Company may repurchase American Depositary Shares (“ADSs”), each representing one ordinary share of the Company, for an aggregate amount of up to $1.0 billion. Repurchases under the Program may be made until and including May 6, 2027.

globenewswire.com - 2026-05-07 06:45:00

BioNTech SE is downgraded to Sell due to declining COVID vaccine revenues, leadership exits, and pipeline uncertainty. BNTX faces €531.9m Q1 net loss, expects €2–3bn 2026 revenues, and plans €1bn share buyback amid €16.8bn cash reserves. Major staff cuts and site exits are underway, targeting €500m annual savings to support the oncology pivot.

seekingalpha.com - 2026-05-06 15:57:41

A German government ​spokesperson said on ‌Wednesday that the loss of ​BioNTech vaccine ​production in the country ⁠can be ​offset by other ​companies.

reuters.com - 2026-05-06 07:44:23

BioNTech SE (BNTX) Q1 2026 Earnings Call Transcript

seekingalpha.com - 2026-05-05 15:21:15

Shares of BioNTech SE (NASDAQ:BNTX) are trading lower on Tuesday as the company reported mixed first-quarter financial results.

benzinga.com - 2026-05-05 12:18:15

The company said it would exit operations at some manufacturing plants in Germany and Singapore, as well as sites it acquired as part of its CureVac takeover.

wsj.com - 2026-05-05 07:26:00

Germany's BioNTech said on Tuesday it would close sites affecting up to 1,860 jobs and buy back up ​to $1 billion worth of its shares, following the announcement ‌of two co-founders quitting the COVID-19 vaccine maker.

reuters.com - 2026-05-05 06:47:04

BioNTech SE (Nasdaq: BNTX) today reported financial results for the three months ended March 31, 2026 and provided an update on its corporate progress.

globenewswire.com - 2026-05-05 06:45:00

Top insights from the latest market news from Thursday, April 23, from The Motley Fool analysts on Team Rule Breakers and Team Hidden Gems.

fool.com - 2026-04-23 09:37:29

BioNTech (BNTX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

zacks.com - 2026-04-22 11:10:51

Results from two early-stage trials offer new hope for a cancer that kills around one in eight patients within five years.

wsj.com - 2026-04-21 17:35:00

MAINZ, Germany, April 21, 2026 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will announce its financial results for the first quarter 2026 on Tuesday, May 5, 2026. Additionally, the Company will host a conference call and webcast that day at 8:00 a.m. ET (2:00 p.m. CET) for investors, financial analysts and the general public to discuss its financial results and provide a corporate update. To access the live conference call via telephone, please register via this link. Once registered, dial-in numbers and a PIN will be provided. It is recommended to register at least one day in advance. The slide presentation and audio of the webcast will be available via this link. Participants may also access the slides and the webcast of the conference call via the “Events & Presentations” page in the Investor Relations section of the Company's website at www.BioNTech.com. A replay of the webcast will be made available shortly after the call and archived on the Company's website for 30 days following the call.

globenewswire.com - 2026-04-21 06:45:00

Zoetis has strong growth prospects and an attractive income program. BioNTech has a rich pipeline that could help jolt the stock as it makes clinical progress.

fool.com - 2026-04-15 17:00:00

Freestone Capital Holdings LLC acquired a new stake in BioNTech SE Sponsored ADR (NASDAQ: BNTX) during the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 7,914 shares of the company's stock, valued at approximately $753,000. A number of other hedge

defenseworld.net - 2026-04-15 04:33:35